公开(公告)号：EP2909218A1

公开(公告)日：2015-08-26

申请号：EP13767185.5

申请日：2013-09-12

申请人： ICL-IP America Inc.

发明人： STOWELL, Jeffrey, K. ,  FRANCISCO, Gerardo ,  WEIL, Edward

IPC分类号： C07F9/40 ,  C08K5/5333

CPC分类号： C08J9/0038 ,  C07F9/4003 ,  C07F9/4006 ,  C08G18/14 ,  C08J2375/04 ,  C08K5/5333 ,  C08L75/04 ,  C09K21/12

摘要： There is provided herein a method of making hydroxymethylphosphonate comprising reacting paraformaldehyde, at least one dialkyl phosphite and at least one trialkyl phosphite, in the presence of at least one amine catalyst.

摘要翻译： 有在使羟甲基膦酸酯包括使多聚甲醛，至少一种二烷基亚磷酸酯和至少一种三烷基亚磷酸酯，在至少一种胺催化剂存在下的方法提供的。

公开(公告)号：EP1986633A2

公开(公告)日：2008-11-05

申请号：EP07705368.4

申请日：2007-02-09

申请人： Summit Corporation Plc

发明人： WYNNE, Graham Michael ,  WREN, Stephen Paul ,  JOHNSON, Peter David ,  PRICE, Paul Damien ,  DE MOOR, Olivier ,  NUGENT, Gary ,  STORER, Richard ,  PYE, Richard Joseph ,  DORGAN, Colin Richard

IPC分类号： A61K31/343 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4709

CPC分类号： C07F9/4003 ,  A61K31/343 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377

摘要： There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

公开(公告)号：EP4327882A3

公开(公告)日：2024-05-15

申请号：EP24150802.7

申请日：2018-09-07

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： LI, Lingyin ,  SMITH, Mark ,  SHAW, Kelsey Erin ,  CAROZZA, Jacqueline Ann ,  BOEHNERT, Volker

IPC分类号： A61K31/519 ,  C07D471/00 ,  A61P35/00

CPC分类号： C07F9/4003 ,  A61K31/519 ,  C07D401/04 ,  C07F5/025 ,  C07F9/00 ,  C07F9/091 ,  C07F9/1651 ,  C07F9/3826 ,  C07F9/4407

摘要： Compounds, compositions and methods are provided for the inhibition of ENPP 1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP 1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.

公开(公告)号：EP1986633B1

公开(公告)日：2014-07-30

申请号：EP07705368.4

申请日：2007-02-09

申请人： Summit Corporation Plc

发明人： WYNNE, Graham Michael ,  WREN, Stephen Paul ,  JOHNSON, Peter David ,  PRICE, Paul Damien ,  DE MOOR, Olivier ,  NUGENT, Gary ,  STORER, Richard ,  PYE, Richard Joseph ,  DORGAN, Colin Richard

IPC分类号： A61K31/343 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4709 ,  A61P21/00

CPC分类号： C07F9/4003 ,  A61K31/343 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377